ConductScience.org, home

Trial · NCT05358639

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

NCT05358639, Phase 1, Active not recruiting, Sunnybrook Health Sciences Centre

3 sourcestrials-2026-11-12-0.4.0

Download JSON
Cite this record

ConductScience Library. Combination of Olaparib and Navitoclax in Women with HGSC and TNBC. Trials, record NCT05358639. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05358639

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
NCT number
NCT05358639
Status
Active not recruiting
Phases
Phase 1
Enrollment
36 participants, estimated
Lead sponsor
Sunnybrook Health Sciences Centre
Conditions
High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer
Interventions
Olaparib tablet, Navitoclax
First posted
2022-05-03
Last updated
2024-11-18

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
Primary
To define a dose and schedule of navitoclax (Recommended Phase II Dose, RP2D) that can be combined safely with Olaparib in women with metastatic recurrent high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC) for further study
2 yearsThe RP2D will be determined based on an evaluation of multiple endpoints, which will include the DLT( dose limiting toxicity) rate.
SecondaryCmax: the maximum drug concentration.2 yearsThe maximum drug concentration will be measured in blood samples as part of the PK profile of olaparib and navitoclax when given in combination.
SecondaryTmax: time to reach the maximum drug concentration.2 yearsThe time to reach maximum drug concentration will be measured in blood samples as part of the PK profile of olaparib and navitoclax when given in combination.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release
trials-2026-11-12-0.4.0
Release manifest SHA-256
0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture
2026-11-12
Results copy, AACT
2026-03-23
NIH clinical studies file
2026-11-13

Source ClinicalTrials.gov

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05358639

GET https://conductscience.org/api/trials/v1/NCT05358639/registered